Comparison of complications and shocks in paediatric and young transvenous and subcutaneous implantable cardioverter-defibrillator patients

被引:17
|
作者
Quast, A. B. E. [1 ]
Brouwer, T. F. [1 ]
Kooiman, K. M. [1 ]
van Dessel, P. F. H. M. [1 ]
Blom, N. A. [2 ]
Wilde, A. A. M. [1 ]
Knops, R. E. [1 ]
机构
[1] Univ Amsterdam, Amsterdam Cardiovasc Sci, Dept Clin & Expt Cardiol, Amsterdam UMC,Heart Ctr, Amsterdam, Netherlands
[2] Univ Amsterdam, Dept Paediat Cardiol, Amsterdam UMC, Amsterdam, Netherlands
关键词
Implantable cardioverter-defibrillator; Device-related complications; Inappropriate therapy; Paediatric; Young; Subcutaneous ICD; CLINICAL-EXPERIENCE; CHILDREN; ADULTS;
D O I
10.1007/s12471-018-1186-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundYoung implantable cardioverter-defibrillator (ICD) patients are prone to complications and inappropriate shocks (IAS). The subcutaneous ICD (S-ICD) may avoid lead-related complications. This study aims to describe the incidence and nature of device-related complications in young transvenous ICD (TV-ICD) and S-ICD patients.MethodsSingle-chamber TV-ICD and S-ICD patients up to and including the age of 25years implanted between 2002 and 2015 were retrospectively analysed. Complications were defined as device-related complications requiring surgical intervention. IAS were defined as shocks for anything other than ventricular tachycardia or ventricular fibrillation. Follow-up data were collected 5years post-implantation. Kaplan-Meier estimates for complications at 5-year follow-up were calculated with acorresponding 95% confidence interval.ResultsEighty-one patients (46TV-ICD, 35S-ICD) were included (median age 19.0 (IQR 16.0-23.0) and 16.5 (IQR 13.0-20.2) years respectively). Median follow-up was 60 and 40months respectively. All-cause complication rate was 34% in the TV-ICD group and 25% in the S-ICD group (p=0.64). TV-ICD patients had more lead complications: 23% (10-36%) versus 0% (p=0.02). The rate of infections did not differ between TV-ICD and S-ICD: 2% (0-6%) versus 10% (0-21%) (p=0.15). No systemic infections occurred in the S-ICD patients. The rates of IAS were similar, TV-ICD 22% (9-35%) versus S-ICD 14% (0-30%) (p=0.40), as were those for appropriate shocks: 25% (11-39%) versus 27% (6-48%) (p=0.92).ConclusionThe rates of all-cause complications in this cohort were equal, though the nature of the complications differed. S-ICD patients did not suffer lead failures or systemic infections. An era effect is present between the two groups.
引用
收藏
页码:612 / 619
页数:8
相关论文
共 50 条
  • [41] Clinical Outcomes of Implantable Cardioverter-Defibrillator in Pediatric Patients
    Song, Mi Kyoung
    Uhm, Jae-Sun
    Baek, Jae Suk
    Yoon, Ja Kyoung
    Na, Jae Yoon
    Yu, Hee Tae
    Yang, Ji-Hyuk
    Oh, Seil
    Park, Sang Weon
    Song, Jinyoung
    Huh, June
    Bae, Eun-Jung
    CIRCULATION JOURNAL, 2021, 85 (08) : 1356 - +
  • [42] Eligibility for subcutaneous implantable cardioverter-defibrillator in congenital heart disease
    Wang, Linda
    Javadekar, Neeraj
    Rajagopalan, Ananya
    Rogovoy, Nichole M.
    Haq, Kazi T.
    Broberg, Craig S.
    Tereshchenko, Larisa G.
    HEART RHYTHM, 2020, 17 (05) : 860 - 869
  • [43] CONSISTENT SUBCUTANEOUS PREPECTORAL IMPLANTATION OF A NEW IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR
    STANTON, MS
    HAYES, DL
    MUNGER, TM
    TRUSTY, JM
    ESPINOSA, RE
    SHEN, WK
    OSBORN, MJ
    PACKER, DL
    HAMMILL, SC
    MAYO CLINIC PROCEEDINGS, 1994, 69 (04) : 309 - 314
  • [44] New surgical approach to implantation of the subcutaneous implantable cardioverter-defibrillator
    Kennergren, Charles E. H.
    EUROPACE, 2017, 19 (12): : 1907 - 1908
  • [45] Incidence of and predictors for appropriate implantable cardioverter-defibrillator therapy in patients with a secondary preventive implantable cardioverter-defibrillator indication
    Schaer, Beat
    Kuehne, Michael
    Reichlin, Tobias
    Osswald, Stefan
    Sticherling, Christian
    EUROPACE, 2016, 18 (02): : 227 - 231
  • [46] Use and outcomes of subcutaneous implantable cardioverter-defibrillator (ICD) after transvenous ICD extraction: An analysis of current clinical practice and a comparison with transvenous ICD reimplantation
    Viani, Stefano
    Migliore, Federico
    Tola, Gianfranco
    Pisano, Ennio C. L.
    Dello Russo, Antonio
    Luzzi, Giovanni
    Sartori, Paolo
    Piro, Agostino
    Rordorf, Roberto
    Forleo, Giovanni Battista
    Rago, Anna
    Segreti, Luca
    Bertaglia, Emanuele
    Biffi, Mauro
    Lovecchio, Mariolina
    Valsecchi, Sergio
    Diemberger, Igor
    Bongiorni, Maria Grazia
    HEART RHYTHM, 2019, 16 (04) : 564 - 571
  • [47] Subcutaneous Implantable Cardioverter-Defibrillator in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: A Transatlantic Experience
    Orgeron, Gabriela M.
    Bhonsale, Aditya
    Migliore, Federico
    James, Cynthia A.
    Tichnell, Crystal
    Murray, Brittney
    Bertaglia, Emanuele
    Cadrin-Tourigny, Julia
    De Franceschi, Pietro
    Crosson, Jane
    Tandri, Harikrishna
    Corrado, Domenico
    Calkins, Hugh
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (21):
  • [48] Benefits of the implantable cardioverter-defibrillator
    Epstein, Andrew E.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 52 (14) : 1122 - 1127
  • [49] Development of the Implantable Cardioverter-Defibrillator
    Maron, Barry J.
    Estes, N. A. Mark
    Rowin, Ethan J.
    Maron, Martin S.
    Reynolds, Matthew R.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 82 (04) : 353 - 373
  • [50] Use of an electrocardiographic screening tool to determine candidacy for a subcutaneous implantable cardioverter-defibrillator
    Groh, Christopher A.
    Sharma, Shishir
    Pelchovitz, Daniel J.
    Bhave, Prashant D.
    Rhyner, John
    Verma, Nishant
    Arora, Rishi
    Chicos, Alexandru B.
    Kim, Susan S.
    Lin, Albert C.
    Passman, Rod S.
    Knight, Bradley P.
    HEART RHYTHM, 2014, 11 (08) : 1361 - 1366